ONEMEDNET CORPORATION Research and Development Expense
ONEMEDNET CORPORATION (ONMD) reported Research and Development Expense of $324.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- ONEMEDNET CORPORATION research and development expense for the quarter ending 2026-06-30 was $324.00K, a 15.18% decline year-over-year.
- ONEMEDNET CORPORATION research and development expense for the quarter ending 2026-03-31 was $311.00K, a 10.63% decline year-over-year.
- ONEMEDNET CORPORATION research and development expense for the quarter ending 2025-12-31 was $443.00K, a 30.29% increase year-over-year.
- ONEMEDNET CORPORATION research and development expense for the quarter ending 2025-09-30 was $323.00K, a 8.39% increase year-over-year.
- ONEMEDNET CORPORATION research and development expense for fiscal 2023 was $2.06M, a 29.79% increase from fiscal 2022.
- ONEMEDNET CORPORATION research and development expense for fiscal 2022 was $1.59M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $324.00K 10-Q · filed 2026-08-14 | $636.00K 10-Q · filed 2026-08-14 | $1.08M derived: sum of 3 quarters · filed 2026-08-14 | $1.40M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $311.00K S-1/A · filed 2026-07-08 | $754.00K derived: sum of 2 quarters · filed 2026-07-08 | $1.08M derived: sum of 3 quarters · filed 2026-07-08 | $1.46M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $443.00K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-07-08 | $766.00K derived: sum of 2 quarters · filed 2026-07-08 | $1.15M derived: sum of 3 quarters · filed 2026-08-14 | $1.51M S-1/A · filed 2026-07-08 | ||
| 2025-09-30 | $323.00K 10-Q · filed 2025-11-14 | $705.00K derived: sum of 2 quarters · filed 2026-08-14 | $1.07M 10-Q · filed 2025-11-14 | $1.39M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $382.00K 10-Q · filed 2026-08-14 | $749.00K 10-Q · filed 2026-08-14 | $1.07M derived: sum of 3 quarters · filed 2026-08-14 | $1.37M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $348.00K S-1/A · filed 2026-07-08 | $688.00K derived: sum of 2 quarters · filed 2026-07-08 | $986.00K derived: sum of 3 quarters · filed 2026-07-08 | $1.37M derived: sum of 4 quarters · filed 2026-07-08 | ||
| 2024-12-31 | $340.00K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-07-08 | $638.00K derived: sum of 2 quarters · filed 2026-07-08 | $1.02M derived: sum of 3 quarters · filed 2026-07-08 | $1.47M S-1/A · filed 2026-07-08 | ||
| 2024-09-30 | $298.00K 10-Q · filed 2025-11-14 | $681.00K derived: sum of 2 quarters · filed 2025-11-14 | $1.13M 10-Q · filed 2025-11-14 | $1.63M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $383.00K 10-Q · filed 2025-08-13 | $828.00K 10-Q · filed 2025-08-13 | $1.33M derived: sum of 3 quarters · filed 2025-08-13 | $1.73M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $445.00K 10-Q · filed 2025-05-14 | $944.00K derived: sum of 2 quarters · filed 2025-05-14 | $1.35M derived: sum of 3 quarters · filed 2025-05-14 | $1.93M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $499.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $904.00K derived: sum of 2 quarters · filed 2025-04-15 | $1.48M derived: sum of 3 quarters · filed 2025-04-15 | $2.06M 10-K · filed 2025-04-15 | $1.63M 10-K · filed 2024-04-09 | |
| 2023-09-30 | $405.00K 10-Q · filed 2024-12-17 | $984.00K derived: sum of 2 quarters · filed 2024-12-17 | $1.57M 10-Q · filed 2024-12-17 | $1.13M 10-Q · filed 2023-11-20 | $2.07M derived: sum of 4 quarters · filed 2024-12-17 | |
| 2023-06-30 | $579.00K 10-Q · filed 2024-12-11 | $1.16M 10-Q · filed 2024-12-11 | $1.66M derived: sum of 3 quarters · filed 2024-12-11 | $2.26M derived: sum of 4 quarters · filed 2024-12-11 | ||
| 2023-03-31 | $582.00K 10-Q · filed 2024-12-05 | $1.08M derived: sum of 2 quarters · filed 2024-12-05 | $1.68M derived: sum of 3 quarters · filed 2024-12-05 | |||
| 2022-12-31 | $503.00K derived: 10-K/A 12 month − 8-K/A 9 month · filed 2024-11-05 | $1.10M derived: sum of 2 quarters · filed 2024-11-22 | $1.59M 10-K/A · filed 2024-11-05 | $952.70K 10-K · filed 2024-04-09 | ||
| 2022-09-30 | $597.00K 8-K/A · filed 2024-11-22 | $1.09M 8-K/A · filed 2024-11-22 | $710.36K 10-Q · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |